AstraZeneca

News

Lilly unveils promising data from dual-action diabetes drug

Eli Lilly’s investigational diabetes drug has shown early promise as a possible aid to overcoming obesity in trial results announced this week.

News

AZ's old R&D site at heart of multimillion pound science pro...

AstraZeneca’s new R&D headquarters in Cambridge may be having teething problems – but ironically the site at Alderley Park, Cheshire that it abandoned nearly five years ago is going fro

News

FDA says Clovis' Rubraca could be prostate cancer breakthrou...

Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out.

News

Novo to market 'connected' insulin pens next year

Novo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate with glucose monitoring systems and glucose meters.

News

AZ grabs EU approval for Imfinzi in advanced lung cancer

The European Commission has approved AstraZeneca’s immunotherapy drug Imfinzi (durvalumab) in a kind of lung cancer that was previously only treatable with chemotherapy.

News

Study shows AZ's Farxiga diabetes drug cuts heart risks

AstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in a clinical trial.

Lilly unveils promising data from dual-action diabetes drug

AZ's old R&D site at heart of multimillion pound science pro...

FDA says Clovis' Rubraca could be prostate cancer breakthrou...

Novo to market 'connected' insulin pens next year

AZ grabs EU approval for Imfinzi in advanced lung cancer

Study shows AZ's Farxiga diabetes drug cuts heart risks

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

AstraZeneca

Editor's Picks